Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effects of Creatine Formulations on Exercise and Cognitive Performance

10 novembre 2026 mis à jour par: Terence Moriarty, University of Northern Iowa

Effects of Creatine Monohydrate Versus a Multi-Ingredient Creatine Formulation on Exercise Performance, Cognitive Function, Hydration, and Gastrointestinal Tolerability

This study will examine whether a multi-ingredient creatine supplement produces different effects on exercise performance, cognitive function, hydration, and gastrointestinal symptoms compared with creatine monohydrate alone.

Approximately 16 healthy, physically active adults aged 18-40 years will participate. Each participant will take creatine monohydrate (5 grams per day) for 18 days and a multi-ingredient supplement containing creatine monohydrate (5 grams), sodium, potassium, magnesium, and taurine for another 18 days. The order of supplementation will be randomly assigned, with a 30-day break between conditions.

Participants will complete laboratory testing before and after each supplementation period. Testing will include bench press exercise to assess muscular endurance, repeated high-intensity cycling tests to assess exercise performance, and a computerized cognitive task to measure attention and reaction time. Researchers will also assess hydration, selected blood markers, perceived exertion, and gastrointestinal symptoms.

The findings may help determine whether adding electrolytes and taurine to creatine provides additional benefits or produces different physiological responses compared with creatine monohydrate alone.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Estimé)

16

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Iowa
      • Cedar Falls, Iowa, États-Unis, 50614
        • Recrutement
        • Wellness and Recreation Center
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 40 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adults aged 18-40 years.
  • Apparently healthy individuals who are physically active and capable of performing vigorous exercise.
  • Willing and able to complete repeated maximal-intensity cycling tests, bench press exercise, and cognitive assessments.
  • Willing to consume both assigned dietary supplement formulations for 18 days each, separated by a 30-day washout period.
  • Willing to refrain from taking additional creatine or electrolyte supplements during the study, including the washout period.
  • Able and willing to provide written informed consent.

Exclusion Criteria:

  • History of cardiovascular, metabolic, renal, neurological, or musculoskeletal conditions that may contraindicate vigorous exercise or interfere with study outcomes.
  • Current injury or physical limitation that would prevent safe completion of the exercise testing procedures.
  • Current pregnancy or plans to become pregnant during the study.
  • Recent creatine supplementation prior to enrollment.
  • Current use of medications or dietary supplements that may interfere with creatine metabolism, hydration status, exercise performance, cognitive function, or participant safety.
  • Known allergy, intolerance, or contraindication to any ingredient in the study supplements.
  • Unwillingness or inability to comply with supplementation, washout, or laboratory testing requirements.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Science basique
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Creatine Monohydrate Followed by Multi-Ingredient Creatine

Participants will receive creatine monohydrate (5 g/day) with sugar-free flavoring for 18 consecutive days, followed by a 30-day washout period. Participants will then receive a multi-ingredient formulation containing creatine monohydrate (5 g/day), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) for an additional 18 days. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after each supplementation period.

Participants will consume 5 g/day of creatine monohydrate mixed with sugar-free flavoring for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period.

Participants will consume a multi-ingredient dietary supplement containing creatine monohydrate (5 g), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) daily for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period.

Expérimental: Multi-Ingredient Creatine Followed by Creatine Monohydrate

Participants will receive a multi-ingredient formulation containing creatine monohydrate (5 g/day), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) for 18 consecutive days, followed by a 30-day washout period. Participants will then receive creatine monohydrate (5 g/day) with sugar-free flavoring for an additional 18 days. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after each supplementation period.

Participants will consume 5 g/day of creatine monohydrate mixed with sugar-free flavoring for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period.

Participants will consume a multi-ingredient dietary supplement containing creatine monohydrate (5 g), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) daily for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Total Bench Press Repetitions
Délai: Baseline and Day 18 of each supplementation period.

Total number of repetitions completed across three sets of bench press exercise at 70% of baseline one-repetition maximum (1RM), performed to volitional fatigue with one minute of rest between sets.

Baseline and Day 18 of each supplementation period.
Peak Power During Repeated Wingate Tests
Délai: Baseline and Day 18 of each supplementation period.

Peak power output (watts) measured during three consecutive 30-second Wingate cycling tests, performed with standardized recovery periods.

Baseline and Day 18 of each supplementation period.
Mean Power During Repeated Wingate Tests
Délai: Baseline and Day 18 of each supplementation period.

Mean power output (watts) measured during each of three 30-second maximal-effort Wingate cycling tests.

Baseline and Day 18 of each supplementation period.
Total Work During Repeated Wingate Tests
Délai: Baseline and Day 18 of each supplementation period.

Total mechanical work (kilojoules) completed across three 30-second Wingate cycling tests.

Baseline and Day 18 of each supplementation period.
Stroop Interference Reaction Time
Délai: Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).

Cognitive performance assessed using a computerized Stroop task completed before exercise and during recovery between repeated Wingate tests. Reaction time (milliseconds) will be used to evaluate changes in cognitive performance as exercise-induced fatigue accumulates.

Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).
Stroop Task Accuracy
Délai: Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).

Percentage of correct responses during a computerized Stroop task administered before exercise and during recovery between repeated Wingate cycling tests.

Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Wingate Fatigue Index
Délai: Baseline and Day 18 of each supplementation period.

Percentage decline in power output during repeated Wingate tests.

Baseline and Day 18 of each supplementation period.
Rating of Perceived Exertion
Délai: Baseline and Day 18 of each supplementation period.

Perceived exertion assessed using the Borg 6-20 scale following each Wingate.

Baseline and Day 18 of each supplementation period.
Blood Lactate Concentration
Délai: Baseline and Day 18 of each supplementation period.

Blood lactate concentration (mmol/L) measured following each Wingate.

Baseline and Day 18 of each supplementation period.
Urine Specific Gravity
Délai: Baseline and Day 18 of each supplementation period.

Urine specific gravity assessed before and after exercise to evaluate hydration status.

Baseline and Day 18 of each supplementation period.
Blood Sodium Concentration
Délai: Baseline and Day 18 of each supplementation period.

Sodium concentration measured using an i-STAT analyzer.

Baseline and Day 18 of each supplementation period.
Blood Potassium Concentration
Délai: Baseline and Day 18 of each supplementation period.

Potassium concentration measured using an i-STAT analyzer.

Baseline and Day 18 of each supplementation period.
Gastrointestinal Symptom Severity
Délai: Baseline and Day 18 of each supplementation period.

Daily 0-10 ratings of bloating, abdominal discomfort, nausea, diarrhea, constipation, reflux, and overall gastrointestinal discomfort.

Baseline and Day 18 of each supplementation period.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

13 novembre 2026

Achèvement primaire (Estimé)

31 mai 2027

Achèvement de l'étude (Estimé)

31 mai 2027

Dates d'inscription aux études

Première soumission

5 novembre 2026

Première soumission répondant aux critères de contrôle qualité

10 novembre 2026

Première publication (Réel)

16 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • IRB-FY27-58

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .